# Anti-Xa Guided Dosing of Low Molecular Weight Heparin for Prevention of Venous Thromboembolism Following Traumatic Injury: a Multicentre Pilot Randomized Trial

> **NCT06662253** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Alexandre Tran** · enrollment: 150 (estimated)

## Conditions studied

- Venous Thromboembolism (VTE)
- Trauma Related Injuries

## Interventions

- **DRUG:** Anti-Xa Guided Dosing of Low Molecular Weight Heparin
- **DRUG:** Standard of Care Dosing

## Key facts

- **NCT ID:** NCT06662253
- **Lead sponsor:** Alexandre Tran
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01
- **Primary completion:** 2026-06
- **Final completion:** 2026-09
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2024-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06662253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06662253, "Anti-Xa Guided Dosing of Low Molecular Weight Heparin for Prevention of Venous Thromboembolism Following Traumatic Injury: a Multicentre Pilot Randomized Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06662253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*